Ultragenyx Pharmaceutical Inc (RARE) announced Loss for third quarter that decreased from last year and beat the Street estimates.
The company's earnings totaled -$133.5 million, or -$1.40 per share. This compares with -$159.6 million, or -$2.23 per share, in last year's third quarter.
Analysts on average had expected the company to earn -$1.45 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 42.2% to $139.5 million from $98.1 million last year.
Ultragenyx Pharmaceutical Inc earnings at a glance (GAAP) :
-Earnings (Q3): -$133.5 Mln. vs. -$159.6 Mln. last year.
-EPS (Q3): -$1.40 vs. -$2.23 last year.
-Revenue (Q3): $139.5 Mln vs. $98.1 Mln last year.
-Guidance:
Full year revenue guidance: $530-$550 mln
For comments and feedback: editorial@rttnews.com